About the Course
This comprehensive heart failure and cardiomyopathy program brings together leading experts to explore the latest breakthroughs shaping cardiovascular care. Designed for clinicians across the spectrum of practice, the course delivers cutting-edge insights into HFrEF, genetic and inflammatory cardiomyopathies, metabolic drivers of heart failure, and the rapidly evolving landscape of precision medicine.
Participants will gain practical, evidence-based strategies for optimizing guideline-directed therapy, interpreting emerging clinical trials, and managing complex conditions such as cardiogenic shock, cardiac amyloidosis, and advanced heart failure requiring mechanical circulatory support or transplant evaluation.
With dedicated sessions on future innovations, multidisciplinary intersections, and real-world clinical challenges, this program equips learners with the knowledge and confidence to deliver timely, personalized, and high-quality care to patients with heart failure and cardiomyopathies.
Who Should Attend?
The course is directed toward physicians, physician assistants, nurse practitioners, nurses, and all healthcare providers with an interest in treating and managing patients with heart failure.
After completing this course, participants will be able to:
- Apply precision medicine principles to the evaluation and management of patients with heart failure across the EF spectrum, incorporating genetic, imaging, metabolic, and phenotypic data into individualized care plans.
- Integrate contemporary evidence since the 2022 guidelines in GDMT, devices, advanced therapies, and obesity/metabolic treatments into day-to-day clinical decision-making for HFrEF and HFpEF.
- Optimize systems of care for complex HF patients by implementing CKM models, population-health strategies, remote monitoring, and equitable access pathways to advanced heart failure therapies.
- Select and manage advanced and critical care therapies with greater precision, including temporary and durable mechanical circulatory support, ECMO configurations, and evolving antithrombotic and allocation strategies for LVAD and heart transplantation.
- Leverage emerging technologies and innovations such as AI, gene and regenerative therapies, and novel diagnostics to enhance early detection, risk stratification, and personalized treatment of cardiomyopathies and cardiac amyloidosis.